Cecilia Acuti Martellucci

Dr. Cecilia Acuti Martellucci

University of Ferrara, Ferrara, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Advances in Biological Regulation
Verified
Journal Article
Closed access
CMCecilia Acuti Martellucci
Cecilia Acuti Martellucci
MFMaria Elena Flacco
Maria Elena Flacco
Rosaria CappadonaRosaria Cappadona
Rosaria Cappadona
FBFrancesca Bravi
Francesca Bravi
LMLorenzo Mantovani
Lorenzo Mantovani
Lamberto ManzoliLamberto Manzoli
Lamberto Manzoli

1 July 2020 in Heart
Verified
Journal Article
Open access
PDF file
MFMaria Elena Flacco
Maria Elena Flacco
CMCecilia Acuti Martellucci
Cecilia Acuti Martellucci
FBFrancesca Bravi
Francesca Bravi
GPGiustino Parruti
Giustino Parruti
Rosaria CappadonaRosaria Cappadona
Rosaria Cappadona
Lamberto ManzoliLamberto Manzoli
Lamberto Manzoli
Objective It has been hypothesised that the use of ACE inhibitors and angiotensin receptor blockers (ARBs) might either increase or reduce the risk of severe or lethal COVID-19. The findings from the available observational studies varied, and summary estimates are urgently needed to elucidate whether these drugs should be suspended during the pandemic, or patients and physicians should be definitely reassured. This meta-analysis of adjusted observational data aimed to summarise the existing evidence on the association between these medications and severe/lethal COVID-19. Methods We searched MedLine, Scopus and preprint repositories up to 8 June 2020 to retrieve cohort or case–control studies comparing the risk of severe/fatal COVID-19 (either mechanical ventilation, intensive care unit admission or death), among hypertensive subjects treated with: (1) ACE inhibitors, (2) ARBs and (3) both, versus untreated subjects. Data were combined using a random-effect generic inverse variance approach. Results Ten studies, enrolling 9890 hypertensive subjects were included in the analyses. Compared with untreated subjects, those using either ACE inhibitors or ARBs showed a similar risk of severe or lethal COVID-19 (summary OR: 0.90; 95% CI 0.65 to 1.26 for ACE inhibitors; 0.92; 95% CI 0.75 to 1.12 for ARBs). The results did not change when both drugs were considered together, when death was the outcome and excluding the studies with significant, divergent results. Conclusion The present meta-analysis strongly supports the recommendation of several scientific societies to continue ARBs or ACE inhibitors for all patients, unless otherwise advised by their physicians who should thus be reassured.

29 July 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
MFMaria Elena Flacco
Maria Elena Flacco
CMCecilia Acuti Martellucci
Cecilia Acuti Martellucci
VBValentina Baccolini
Valentina Baccolini
CVCorrado De Vito
Corrado De Vito
ERErika Renzi
Erika Renzi
Lamberto ManzoliLamberto Manzoli
Lamberto Manzoli
Introduction: A precise estimate of the frequency and severity of SARS‐CoV‐2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta‐analysis to evaluate the risk of reinfection and COVID‐19 following primary infection.Methods: We searched MedLine, Scopus and preprint repositories for cohort studies evaluating the onset of new infections among baseline SARS‐CoV‐2‐positive subjects. Random‐effect meta‐analyses of proportions were stratified by gender, exposure risk, vaccination status, viral strain, time between episodes, and reinfection definition.Results: Ninety‐one studies, enrolling 15,034,624 subjects, were included. Overall, 158,478 reinfections were recorded, corresponding to a pooled rate of 0.97% (95% CI: 0.71%–1.27%), with no substantial differences by definition criteria, exposure risk or gender. Reinfection rates were still 0.66% after ≥12 months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3 months of Omicron wave, the reinfection rates reached 3.31%. Overall rates of severe/lethal COVID‐19 were very low (2–7 per 10,000 subjects according to definition criteria) and were not affected by strain predominance.Conclusions: A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low. The risk–benefit profile of multiple vaccine doses for this subset of population needs to be carefully evaluated.

24 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FBFrancesca Bravi
Francesca Bravi
MFMaria Elena Flacco
Maria Elena Flacco
TCTiziano Carradori
Tiziano Carradori
CVCarlo Alberto Volta
Carlo Alberto Volta
GCGiuseppe Cosenza
Giuseppe Cosenza
Lamberto ManzoliLamberto Manzoli
Lamberto Manzoli
This retrospective case-control study was aimed at identifying potential independent predictors of severe/lethal COVID-19, including the treatment with Angiotensin-Converting Enzyme inhibitors (ACEi) and/or Angiotensin II Receptor Blockers (ARBs). All adults with SARS-CoV-2 infection in two Italian provinces were followed for a median of 24 days. ARBs and/or ACEi treatments, and hypertension, diabetes, cancer, COPD, renal and major cardiovascular diseases (CVD) were extracted from clinical charts and electronic health records, up to two years before infection. The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (154 deaths; mean age 79.3 years; 70.8% hypertensive, 42.2% with CVD). The youngest deceased person aged 44 years. Among hypertensive subjects (n = 543), the proportion of those treated with ARBs or ACEi were 88.4%, 78.7% and 80.6% among patients with mild, severe and very severe/lethal disease, respectively. At multivariate analysis, no association was observed between therapy and disease severity (Adjusted OR for very severe/lethal COVID-19: 0.87; 95% CI: 0.50–1.49). Significant predictors of severe disease were older age (with AORs largely increasing after 70 years of age), male gender (AOR: 1.76; 1.40–2.23), diabetes (AOR: 1.52; 1.05–2.18), CVD (AOR: 1.88; 1.32–2.70) and COPD (AOR: 1.88; 1.11–3.20). Only gender, age and diabetes also predicted very severe/lethal disease. No association was found between COVID-19 severity and treatment with ARBs and/or ACEi, supporting the recommendation to continue medication for all patients unless otherwise advised by their physicians.

13 October 2020 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
DMDaniele Di Mascio
Daniele Di Mascio
Asma KhalilAsma Khalil
Asma Khalil
Giuseppe RizzoGiuseppe Rizzo
Giuseppe Rizzo
DBDANILO BUCA
DANILO BUCA
MLM. Liberati
M. Liberati
FDFrancesco D'Antonio
Francesco D'Antonio

22 January 2022 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
Giovanni MartinottiGiovanni Martinotti
Giovanni Martinotti
MPMauro Pettorruso
Mauro Pettorruso
CMChiara Montemitro
Chiara Montemitro
PSPrimavera Alessandra Spagnolo
Primavera Alessandra Spagnolo
CMCecilia Acuti Martellucci
Cecilia Acuti Martellucci
MGMassimo di Giannantonio
Massimo di Giannantonio